Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 5
Gernot Warnke, Head of R&D, JRS Pharma, spoke about excipients and how these relate to feeding in batch and continuous manufacturing.
Equipment and advanced manufacturing approaches to meet the evolving needs for solid-dosage drugs include continuous manufacturing, containment strategies, Industry 4.0 tools, and techniques for optimizing solid dosage form manufacturing. “Equipment Trends in Advanced Solid-Dosage Drug Manufacturing” was part of a keynote series at INTERPHEX 2021 on Oct. 19, 2021.
The session was moderated by Jennifer Markarian, manufacturing editor, Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International. In this video, Jennifer interviewed Gernot Warnke, Head of R&D, JRS Pharma, who spoke about excipients and how these relate to feeding in batch and continuous manufacturing of oral solid dosage (OSD) drugs.
This video is part 5 of 5. The other speakers in this session were:
- Part 1: Dave DiProspero, Director Pharmaceutical Process Technology, CRB
- Part 2: Johannes Khinast, PhD, Institute for Process and Particle Engineering in the Research Center Pharmaceutical Engineering (RCPE) at the Graz University of Technology in Austria
- Part 3: Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University
- Part 4: Sharon Nowak, Business Development Manager, Coperion K-Tron USA Food & Pharmaceutical Industries.
Watch other videos in this keynote series:
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
